

# Genesis Oncology Trust

## Financial Statements

For the Period Ended 30 June 2008

### Contents

Trust Directory .....	1
Statement of Financial Performance .....	2
Statement of Movements in Equity .....	3
Statement of Financial Position.....	4
Notes to the Financial Statements.....	5
Audit Report.....	10

# Genesis Oncology Trust

## Trust Directory

For the Period Ended 30 June 2008

---

### DATE OF DEED :

17 May 2002

### REGISTERED OFFICE :

602 Great South Road  
Greenlane  
AUCKLAND

### TRUSTEES :

Murray Egerton Jackson  
John Bevan Gavin  
Maureen Grant Shaddick  
Alan Gray  
Betsy Marshall  
Helen Glasgow

### TRUSTS CHARITABLE PURPOSE :

- a) to promote research in NZ into the detection, diagnosis and treatment of all forms of cancer and to provide associated training for health professionals;
- b) to promote the provision of palliative care;
- c) to assist hospitals, and associated health care providers with the provision of facilities in relation to oncology;
- d) to promote such other charitable purposes as the trustees may decide.

### BANKERS :

Westpac  
627 Great South Road  
MANUKAU

### SOLICITORS :

Taylor Grant Tesiram  
P O Box 4039  
AUCKLAND

### AUDITORS:

Deloitte.  
P O Box 17  
Hamilton

# Genesis Oncology Trust

## Statement of Financial Performance

As at 30 June 2008

	NOTE	2008	2007
<b>REVENUE</b>			
Interest Received		-	490,378
Interest Received-Current Account		88,673	-
Interest Received-Bonds		200,236	-
Interest Received-Shares		213,735	-
Interest Received – Shares Rebates		3,529	-
Interest Received-NZD WRAP Account		42,006	-
Interest Received-AUD WRAP Account		308	-
Interest Received-GBP WRAP Account		8,172	-
	2	556,659	490,378
Sponsorship Received – Genesis Power Limited	3	200,000	200,000
Camellia and Stick Sales		-	3,462
Trust Expenditure Reimbursed	4	235,852	261,392
Donations Received – General		918,342	948,451
Unrealised Gain-Current Account		276	-
Unrealised Gain-Investment Shares		-	32,077
<b>TOTAL REVENUE</b>		<b>1,911,129</b>	<b>1,935,760</b>
<b>OPERATING EXPENSES</b>			
Advertising		103,313	179,778
Annual Report Costs		38,931	25,000
Audit Fees		7,000	5,000
Bank Transaction Charges		475	371
Bank Transaction Charges-Shares		153	5,452
Fees-Premium Advisor Service		-	20,900
Fees-Premium Plus Service		57,158	8,961
Consultants		41,528	40,136
Depreciation		-	324
General Expenses		4,050	6,797
Printing		56,510	69,162
Promotions		24,971	-
Unrealised Loss-Investment Shares		986,531	186,616
Website Costs		803	824
		1,321,423	549,317
<b>GRANTS</b>			
Grants Allocated		552,487	569,142
<b>TOTAL EXPENSES</b>		<b>1,873,910</b>	<b>1,118,459</b>
<b>RESIDUAL INCOME CURRENT YEAR</b>		<b>37,219</b>	<b>817,302</b>

**Genesis Oncology Trust**  
**Statement of Movements in Equity**  
For the Period Ended 30 June 2008

---

	NOTE	2008	2007
Opening Equity		9,337,444	8,520,142
Residual Income Current Year		37,219	817,302
<b><u>EQUITY AT END OF YEAR</u></b>		<b><u>9,374,663</u></b>	<b><u>9,337,444</u></b>


# Genesis Oncology Trust

## Statement of Financial Position

As at 30 June 2008

	NOTE	2008	2007
<b>ACCUMULATED FUNDS</b>			
Opening Equity		9,337,444	8,520,142
Residual Income Current Year		37,219	817,302
<b>TOTAL ACCUMULATED FUNDS</b>		<b>9,374,663</b>	<b>9,337,444</b>
<b>REPRESENTED BY:</b>			
<b>CURRENT ASSETS</b>			
Westpac Current Account		593,204	824,424
Westpac Wrap Cash NZD Account		531,049	411,835
Westpac Wrap Cash AUD Account		-	1,833
Westpac Wrap Cash GBP Account	7	1,316	-
Accounts Receivable	6	302,953	269,336
Accrued Interest on Investment		18,483	46,244
GST Refunds Due		-	12,893
<b>TOTAL CURRENT ASSETS</b>		<b>1,447,005</b>	<b>1,566,565</b>
<b>NON-CURRENT ASSETS</b>			
Investments-Bonds		3,577,610	3,305,848
Investments-Shares		5,122,877	5,254,083
<b>TOTAL NON-CURRENT ASSETS</b>	5	<b>8,700,487</b>	<b>8,559,931</b>
<b>TOTAL ASSETS</b>		<b>10,147,492</b>	<b>10,126,496</b>
<b>CURRENT LIABILITIES</b>			
Accounts Payable		34,225	30,036
GST Payable		11,019	-
<b>TERM LIABILITIES</b>			
Provision for Grants		727,585	759,017
<b>TOTAL LIABILITIES</b>		<b>772,829</b>	<b>789,053</b>
<b>NET ASSETS</b>		<b>9,374,663</b>	<b>9,337,444</b>

Trustee:



Dated: 18/9/08

# **Genesis Oncology Trust**

## **For the Year Ended 30 June 2008**

---

### **1 STATEMENT OF ACCOUNTING POLICIES**

These Financial Statements are presented in accordance with Generally Accepted Accounting Practice.

#### **A GENERAL ACCOUNTING POLICIES**

The general accounting policies recognised as appropriate for the measurement and reporting of results, and financial position, under the historical cost method have been followed in the preparation of these financial statements.

The trust promotes the charitable purpose of cancer research and provides assistance to cancer health care providers.

#### **B PARTICULAR ACCOUNTING POLICIES**

The following particular accounting policies, which significantly affect the measurement of residual income and financial position, have been applied.

##### **Differential Reporting**

The trust qualifies for differential reporting because it is not large and is not publicly accountable.

The trust has taken advantage of all differential reporting exemptions with the exception of FRS 19 Accounting for GST.

These financial statements are not prepared under NZ equivalents to International Financial Reporting Standards (NZ IFRS) as the NZ Accounting Standards Board gave a temporary exemption from mandatory conversion for small organisations which fit the criteria for differential reporting.

##### **Income Tax**

The trust has charitable status under the Income Tax Act and is exempt from income tax.

##### **Accounts Receivable**

Accounts receivable are stated at estimated realisable value. Amounts not considered recoverable are written off when identified as such.

##### **Distinction Between Capital and Revenue**

Capital expenditure is defined as all expenditure on the purchase or creation of new property, plant and equipment, and any expenditure, which results in a significant improvement to the original functionality of an existing asset.

# Genesis Oncology Trust

For the Year Ended 30 June 2008

---

Revenue expenditure is defined as expenditure that restores an asset to its original operating capability and all expenditure incurred in maintaining assets used in operating the business.

## Property Plant & Equipment

All property, plant and equipment is initially recorded at cost.

Depreciation of property, plant and equipment, other than freehold land, is charged on a straight line basis so as to apportion the cost of the assets less their estimated residual value over their expected remaining useful lives.

Estimated useful life – software	4 years
----------------------------------	---------

## Investments

The Trust's investment funds have been placed in Westpac's PremiumPlus Service Portfolio in the form of investment bonds and investment shares.

Investment Bonds are recorded at cost. Any premium or discount to maturity value is recognised as an interest expense/income over the remaining period to maturity.

Investment income is accounted for on an accrual basis.

Investment Shares are initially recorded at cost and subsequently adjusted to fair value. Any fair value adjustments are treated as unrealized gains/losses in the statement of financial performance.

Distributions are recognized as they are received.

## Grants & Distributions

Grants are included in the Statement of Financial Performance when approved by Trustees.

## Donations Received

Donations are recognised on a cash receipts basis, with the exception of the monthly donations from Genesis Energy customer accounts. This is accrued at year end.

## Sponsorship Received

Sponsorship funding is recognised on an accruals basis as per sponsorship agreements.

# Genesis Oncology Trust

## For the Year Ended 30 June 2008

---

### Goods and Services Tax

All revenue and expense transactions are recorded net of GST. Where applicable, all assets and liabilities have been stated net of GST with the exception of receivables and payables which are stated inclusive of GST.

### Foreign Currencies

Foreign currency transactions are recorded at the exchange rates in effect at the date of the transaction.

### Financial Instruments

All financial instruments are recognized in the statement of financial position. The trust has not entered into any off-balance sheet instruments. The fair value of the financial instruments represents the carrying value of these items as recorded in the financial statements. The maximum exposure to credit risk is represented by the carrying value of each financial asset in the Statement of Financial Position.

## C CHANGES IN ACCOUNTING POLICIES

There have been no changes to accounting policies throughout the year.



# Genesis Oncology Trust

For the Year Ended 30 June 2008

	2008	2007
	\$	\$
<b>2 INTEREST RECEIVED</b>		
Westpac Current Account	88,649	54,607
Westpac Short Term Investment	-	209,925
Westpac WRAP Cash Accounts	267,751	20,401
Investment Portfolio	200,236	205,401
Interest on GST Refunds	24	43
	<u>556,659</u>	<u>490,378</u>

The Westpac current account interest rate has ranged between 7.68 – 8.19%.

Investment portfolio coupon interest rates ranged from 6.39 - 8.0%

## **3 SPONSORSHIP REVENUE**

### **Genesis Power Limited**

	<u>200,000</u>	<u>200,000</u>
--	----------------	----------------

As per the Genesis Power Limited sponsorship agreement with the Trust the annual amount of sponsorship for the year ended 30 June 2008 is \$200,000. (2007: \$200,000)

## **4 RELATED PARTIES**

In addition to the sponsorship transaction above, Genesis Power Limited facilitates its customers making donations via their monthly energy accounts.

Genesis Power Limited paid expenses incurred by the Trust for the year ended 30 June 2008 of \$235,852. (2007: \$261,392)

Genesis Power Limited provides the Trust with accounting and administrative support free of charge.

Murray Egerton Jackson is the Chief Executive of Genesis Power Limited and the Chairman of the Trust.

Maureen Grant Shaddick is the General Counsel and Company Secretary of Genesis Power Limited and is the Deputy Chair of the Trust.

# Genesis Oncology Trust

For the Year Ended 30 June 2008

## 5 INVESTMENTS

All of the investments held by the Trust are publicly traded bonds and shares. The total carrying value is \$8,700,487 (2007: \$8,559,931), with a face value of \$8,700,487 (2007: \$8,463,889). Maturity date of the bonds range from August 2006 to March 2016. The coupon rates range from 6.39% to 8.00%.

## 6 ACCOUNTS RECEIVABLE

Related Party Receivables	302,953	266,609
Other	-	2,727
	<u>302,953</u>	<u>269,336</u>

## 7 FOREIGN CURRENCIES

Westpac WRAP Cash AUD Account	<u>-</u>	<u>1,833</u>
-------------------------------	----------	--------------

As at balance date the Trust had AUD \$0 (NZD \$0) in its Westpac Wrap AUD Cash Account (2007: \$1,833)

Westpac WRAP Cash GBP Account	<u>1,316</u>	<u>-</u>
-------------------------------	--------------	----------

As at balance date the Trust had GBP \$503.63 (NZD \$1,316) in its Westpac Wrap GBP Cash Account (2007: \$0)

## AUDIT REPORT TO THE TRUSTEES OF GENESIS ONCOLOGY TRUST

We have audited the financial statements on pages 2 to 9. The financial statements provide information about the past financial performance of Genesis Oncology Trust and its financial position as at 30 June 2008. This information is stated in accordance with the accounting policies set out on pages 5 to 7.

### Trustees Responsibilities

The Trustees are responsible for the preparation, in accordance with New Zealand law and generally accepted accounting practice, of financial statements which fairly reflect the financial position of Genesis Oncology Trust as at 30 June 2008 and the results of operations for the year ended on that date.

### Auditors' Responsibilities

It is our responsibility to express to you an independent opinion on the financial statements presented by the Trustees

### Basis of Opinion

An audit includes examining, on a test basis, evidence relevant to the amounts and disclosures in the financial statements. It also includes assessing:

- the significant estimates and judgements made by Trustees in the preparation of the financial statements, and
- whether the accounting policies are appropriate to the Genesis Oncology Trust circumstances, consistently applied and adequately disclosed.

We conducted our audit in accordance with New Zealand Auditing Standards. We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to obtain reasonable assurance that the financial statements are free from material misstatements, whether caused by fraud or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Other than in our capacity as auditor, we have no relationship with or interests in Genesis Oncology Trust.

### Unqualified Opinion

We have obtained all the information and explanations that we have required.

In our opinion the financial statements on pages 2 to 9, fairly reflect the financial position of Genesis Oncology Trust as at 30 June 2008 and the results of its operations for the year ended on that date.

Our audit was completed on 18 September 2008 and our unqualified opinion is expressed as at that date.



Chartered Accountants  
HAMILTON, NEW ZEALAND

This audit report relates to the financial statements of Genesis Oncology Trust for the year ended 30 June 2008 included on Genesis Oncology Trust's website. The Trustees are responsible for the maintenance and integrity of Genesis Oncology Trust's website. We have not been engaged to report on the integrity of Genesis Oncology Trust's website. We accept no responsibility for any changes that may have occurred to the financial statements since they were initially presented on the website. The audit report refers only to the financial statements named above. It does not provide an opinion on any other information which may have been hyperlinked to/from these financial statements. If readers of this report are concerned with the inherent risks arising from electronic data communication they should refer to the published hard copy of the audited financial statements and related audit report dated 18 September 2008 to confirm the information included in the audited financial statements presented on this website. Legislation in New Zealand governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.